NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will receive updates through a portfolio monitoring software [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [6].

NEW YORK, Aug. 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO).Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/alto-neuroscience-inc-loss-submission-form/?id=162496&from=4CLASS PERIOD: This laws ...

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant a ...

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its drug ALTO-100, which failed to meet primary endpoints in clinical trials, leading to significant stock price decline [3][4][5]. Group 1: Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company focused on developing treatments for major depressive disorder (MDD) [3]. - The company conducted its initial public offering (IPO) on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Group 2: Allegations and Impact - The lawsuit claims that during the Class Period, Alto Neuroscience made false or misleading statements about the effectiveness of ALTO-100, overstating its clinical and commercial prospects [4]. - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - As of the filing of the class action, Alto Neuroscience's stock continues to trade below the IPO price of $16.00 per share [6].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against the Company - The complaint alleges that the effectiveness of Alto's product pipeline, specifically ALTO-100, in treating major depressive disorder was overstated [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were misrepresented, leading to an inflated perception of Alto's business and financial outlook [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and fraud, emphasizing the importance of responsible business practices [6].

SAN DIEGO, Aug. 18, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit for certain investors in shares of Alto Neuroscience, Inc. (NYSE: ANRO).Investors who purchased in excess of $100,000 in shares of Alto Neuroscience, Inc. (NYSE: ANRO) between February 2, 2024 and October 22, 2024, have certain options and there are short and strict deadlines running. Deadline: September19, 2025. NYSE: ANRO investors should contact the Shareholders Foundation at [ ...

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

Core Viewpoint - A class action has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Allegations and Misleading Information - The Offering Documents related to the IPO were claimed to be negligently prepared, leading to misinformation about ALTO-100's effectiveness in treating major depressive disorder (MDD) [2]. - It was alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, which in turn inflated Alto's business and financial outlook [2]. Group 2: Clinical Trial Results and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial for MDD, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, representing a 69.99% decline, closing at $4.36 per share on October 23, 2024 [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].